FDA Submission Update for ANDA220143 by Hetero Labs
Hetero Labs Limited has submitted ANDA220143 with a standard review priority.
Published: July 20, 2026
Updated: July 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Not specified
Company: Hetero Labs
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hetero Labs
Asset
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
The submission of ANDA220143 by Hetero Labs signifies a potential shift in the competitive landscape of the generic drug market. Portfolio teams need to evaluate how this could affect pricing strategies and market dynamics in the relevant therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review progress and any subsequent approvals or market entries related to ANDA220143.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.